Use of short term genotoxicological tests to study cytotoxic, genotoxic and cell death mechanism of Metronidazole
Metronidazole (MTZ) is a wonderful drug, which is used clinically to treat a wide range of bacterial and protozoal infections. This study aimed to achieve a precise characterization of the cytotoxic and genotoxic activities of MTZ in cultured human lymphocytes at therapeutic concentrations and to ev...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2010
|
| Materias: | |
| Acceso en línea: | Registro en Scopus Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 09287caa a22011657a 4500 | ||
|---|---|---|---|
| 001 | PAPER-7431 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518203710.0 | ||
| 008 | 190411s2010 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-78751638338 | |
| 024 | 7 | |2 cas |a metronidazole, 39322-38-8, 443-48-1 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 100 | 1 | |a López Nigro, M.M. | |
| 245 | 1 | 0 | |a Use of short term genotoxicological tests to study cytotoxic, genotoxic and cell death mechanism of Metronidazole |
| 260 | |c 2010 | ||
| 270 | 1 | 0 | |m López nigro, M. M.; CIGETOX (Citogenética Humana y Genética Toxicológica), INFIBIOC (Instituto de Fisiolopatología y Bioquímica Clínica), Facultad de Farmacia y Bioquímica Universidad de Buenos Aires, Junín 956 (C1113AAD), Ciudad Autónoma de Buenos Aires, Argentina; email: mmlopeznigro@gmail.com |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Freeman, C.D., Klutman, N.E., Lamp, K.C., (1997) Drugs, 54, pp. 679-708 | ||
| 504 | |a Thapa, P.B., Whitlock, J.A., Worrell, B.K.G., Gideon, P., Mitchel Jr, E.F., Roberson, P., Pais, R., Ray, W.A., (1998) Cancer, 83, pp. 1461-1468 | ||
| 504 | |a (1999) Who Drug Information, 13, pp. 249-262. , World Health Organization, Essential Drugs | ||
| 504 | |a Sisson, G., Jeong, J.Y., Goodwin, A., Bryden, L., Rossler, N., Lim-Morrison, S., Raudonikiene, A., Hoffman, P.S., (2000) J. Bacteriol, 182, pp. 5091-5096 | ||
| 504 | |a Dobías, L., Cerná, M., Rösner, P., Srám, R., (1994) Mutat. Res, 317, pp. 177-194 | ||
| 504 | |a Mudry, M.D., Martínez-Flores, I., Palermo, A.M., Carballo, M.A., Egozcue, J., Garcíacaldés, M., (2001) Teratog. Carcinog. Mutag, 21, pp. 197-205 | ||
| 504 | |a Tocher, J.H., Edwards, D.I., (1994) Biochem. Pharmacol, 48, pp. 1089-1094 | ||
| 504 | |a Reitz, M., Rumpf, M., Knitza, R., (1991) Arzneimit-telforschung, 41, pp. 155-156 | ||
| 504 | |a Reitz, M., Rumpf, M., Knitza, R., (1991) Drug Res, 41, pp. 65-69 | ||
| 504 | |a Edwards, D.I., (1993) J. Antibiot. Chemother, 31, pp. 9-20 | ||
| 504 | |a Trinh, S., Rysset, G., (1998) Mutat. Res, 398, pp. 55-65 | ||
| 504 | |a Espinosa-Aguirre, J.J., De la, T.R.A.I., Lares-Asseff, J., Rubio, V., Dorado, M., Wong Hernández, J.M., (1996) Mutat. Res, 359, pp. 133-140 | ||
| 504 | |a Bendesky, A., Menéndez, D., Ostrosky-Wegman, P., (2002) Mutat. Res, 511, pp. 133-144 | ||
| 504 | |a (1987) Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs, 7-42 (SUPPL. 7), pp. 250-252. , IARC (International Agency for Research on Cancer), Monographs on the Evaluation of Carcinogenic Risk to Humans, International Agency for Research on Cancer, Lyon, France | ||
| 504 | |a El-Nahas, A.F., El-Ashmawy, I.M., (2004) Pharmacol. & Toxicol, 94, pp. 226-231 | ||
| 504 | |a Tucker, J.D., Preston, R.J., (1996) Mutat. Res, 365, pp. 147-159 | ||
| 504 | |a Rajewsky, M.F., Engelbergs, J., Thomale, J., Schweer, T., (2000) Mutat. Res, 462, pp. 101-105 | ||
| 504 | |a Green, D.R., Reed, J.C., (1998) Science, 281, pp. 1309-1312 | ||
| 504 | |a National library of Medicine. Drug Information (2001), http://www.nlm.nih.gov/medlineplus/druginfo/, Medlineplus, Available at; Martindale, W., (1993) Antiprotozoal Agents, in The Extra Pharmacopoeia, pp. 516-523. , (JEF Reynolds, ed.), The Pharmaceutical Press, London | ||
| 504 | |a (2007), http://www.prvademecum.com/, PR Vademecum on-line Argentina, Available at; Carballo, M.A., Mudry, M., Larripa, I., Villamil, E., D'aquino, M., (1992) Mutat. Res, 279, pp. 245-253 | ||
| 504 | |a Perry, P., Wolff, S., (1974) Nature (London), 261, pp. 156-161 | ||
| 504 | |a Rojas, E., Herrera, L.A., Sordo, M., Gonsebatt, M.E., Montero, R., Rodríguez, R., Ostrosky-wegman, P., (1993) Anti-Cancer Drugs, 4, pp. 637-640 | ||
| 504 | |a (1985) Environmental Health Criteria 46. Guidelines for the Study of Genetic Effects in Human Populations, pp. 45-54. , IPCS/International Program on Chemical Safety, WHO, Geneva | ||
| 504 | |a Aw, T.Y., Nicotera, P., Manzo, L., Orrenius, S., (1990) Arch. Biochem. Biophys, 283, pp. 46-50 | ||
| 504 | |a Cohen, J.J., Duke, R.C., (1992) Apoptosis Annu. Rev. Immunol, 10, pp. 267-293 | ||
| 504 | |a Hotz, M.A., Gong, J., Traganos, F., (1994) Cytometry, 15, pp. 237-244 | ||
| 504 | |a Nicoletti, I., Migliorati, G., Pagliacci, M.C., Grignani, F., Riccardi, C., (1991) J. Immunol. Methods, 139, pp. 271-280 | ||
| 504 | |a Lópeznigro, M.M., Palermo, A.M., Mudry, M.D., Carballo, M.A., (2003) Toxicol. In Vitro, 17, pp. 35-40 | ||
| 504 | |a Swierenga, S., Heddle, J., Sigal, D., Gilman, J., Brillinger, R., Douglas, G., Nestmann, E., (1991) Mutat. Res, 246, pp. 301-322 | ||
| 504 | |a Horváthová, E., Slamenová, D., Hlincíková, L., Mandal, T.K., Gábelová, A., Collins, A.R., (1998) Mutat. Res, 409, pp. 163-171 | ||
| 504 | |a Mudry, M.D., Carballo, M.A., De Vinuesa, L.M., Gonzálezcid, M., Larripa, I., (1994) Mutat. Res, 305, pp. 127-132 | ||
| 504 | |a Martelli, A., Allaven, A., Robbiano, L., Mattioli, F., Giovanni, B., (1990) Pharmacol. Toxicol, 66, pp. 329-334 | ||
| 504 | |a Palermo, A.M., Reynoso, A.S., Lópeznigro, M., Mudry, M.D., Carballo, M.A., (2004) Birth Defects Res. A: Clin. Mol. Teratol, 70, pp. 157-162 | ||
| 504 | |a Mudry, M.D., Palermo, A.M., Merani, S., Carballo, M.A., (2007) Reproductive Toxicol, 23, pp. 246-252 | ||
| 504 | |a Carballo, M.A., Palermo, A.M., Mudry, M.D., (2004) Ann. Trop. Med. Parasitol, 98, pp. 139-147 | ||
| 504 | |a Ré, J.L., de Méo, M.P., Laget, M., Guiraud, H., Castegnaro, M., Vanelle, P., Duménil, G., (1997) Mutat. Res, 375, pp. 147-155 | ||
| 504 | |a Nagai, F., Hiyoshi, Y., Sugimachi, K., Tamura, H., (2002) Biol. Pharm. Bull, 25, pp. 383-385 | ||
| 504 | |a Kravtsov, V.D., Daniel, T.O., Koury, M.J., (1999) Am. J. Pathol, 155, pp. 1327-1339 | ||
| 504 | |a Brezden, C.B., McClelland, R.A., Rauth, A.M., (1997) Br. J. Cancer, 76, p. 18088 | ||
| 504 | |a Lecoeur, H., (2002) Exp. Cell Res, 277, pp. 1-14 | ||
| 504 | |a Nasirudeen, A.M.A., Hian, Y.E., Singh, M., Tan, K.S.W., (2004) Microbiology, 150, pp. 33-43 | ||
| 520 | 3 | |a Metronidazole (MTZ) is a wonderful drug, which is used clinically to treat a wide range of bacterial and protozoal infections. This study aimed to achieve a precise characterization of the cytotoxic and genotoxic activities of MTZ in cultured human lymphocytes at therapeutic concentrations and to evaluate the possible cell death mechanism associated with it. A significant decrease in Mitotic Index (P < 0.001) as well as an increase in Sister Chromatid Exchange (P < 0.001) and Chromosomal Aberrations (P < 0.001) frequencies with no modifications in Replication Index was observed. DNA extracts of MTZ treated cells resulted in nucleosomal DNA ladder pattern after 48 h of cell treatment and this pattern correlated with a decrease in cellular viability (P < 0.001), morphological evidence of apoptosis and increase in the percentage of nuclei with hypodiploid DNA content (P < 0.001). We concluded that MTZ is genotoxic, cytotoxic and is able to modulate cell death through apoptotic mechanisms in the experimental design employed. |l eng | |
| 593 | |a CIGETOX (Citogenética Humana y Genética Toxicológica), INFIBIOC (Instituto de Fisiolopatología y Bioquímica Clínica), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 (C1113AAD), Ciudad Autónoma de Buenos Aires, Argentina | ||
| 593 | |a GIBE-Grupo de Investigación en Biología Evolutiva, Dpto. Ecología, Genética y Evolución, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pab. II (C1428EHA), Ciudad Autónoma de Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a CELL DEATH |
| 690 | 1 | 0 | |a CYTOTOXICITY |
| 690 | 1 | 0 | |a GENETIC TOXICOLOGY |
| 690 | 1 | 0 | |a GENOTOXICITY |
| 690 | 1 | 0 | |a METRONIDAZOLE |
| 690 | 1 | 0 | |a SHORT TERM TESTS |
| 690 | 1 | 0 | |a METRONIDAZOLE |
| 690 | 1 | 0 | |a ADULT |
| 690 | 1 | 0 | |a APOPTOSIS |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CELL DEATH |
| 690 | 1 | 0 | |a CELL VIABILITY |
| 690 | 1 | 0 | |a CHROMOSOME ABERRATION |
| 690 | 1 | 0 | |a CHROMOSOME REPLICATION |
| 690 | 1 | 0 | |a CONCENTRATION RESPONSE |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a DIPLOIDY |
| 690 | 1 | 0 | |a DNA CONTENT |
| 690 | 1 | 0 | |a DNA STRUCTURE |
| 690 | 1 | 0 | |a DRUG CYTOTOXICITY |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a GENOTOXICITY |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a HUMAN CELL |
| 690 | 1 | 0 | |a LYMPHOCYTE |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a MITOSIS INHIBITION |
| 690 | 1 | 0 | |a SISTER CHROMATID EXCHANGE |
| 690 | 1 | 0 | |a TOXICITY TESTING |
| 653 | 0 | 0 | |a flagyl, Aventis, Argentina |
| 700 | 1 | |a Mudry, M.D. | |
| 700 | 1 | |a Carballo, M.A. | |
| 773 | 0 | |d 2010 |g v. 29 |h pp. 1319-1327 |k n. 8 |p Lat. Am. J. Pharm. |x 03262383 |t Latin American Journal of Pharmacy | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-78751638338&partnerID=40&md5=3f4a68c0f8348d3b102e4942f2a7aa1e |y Registro en Scopus |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_03262383_v29_n8_p1319_LopezNigro |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03262383_v29_n8_p1319_LopezNigro |y Registro en la Biblioteca Digital |
| 961 | |a paper_03262383_v29_n8_p1319_LopezNigro |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 68384 | ||